MUNICH, Germany – Aigora supported the external validation of AI models developed by Owkin (now Waiv) to predict microsatellite instability (MSI) status from routine H&E-stained pathology slides in gastric, endometrial and biliary tract cancers. The results were published in Laboratory Investigation, with co-authorship from Aigora’s team, and presented at the 2026 USCAP Annual Meeting.
MSI is an important biomarker in cancer care, but its prevalence varies widely between tumour types, so many samples have to be tested to identify relatively few MSI-high (MSI-H) cases. An AI-based pre-screening step on routine slides could help focus confirmatory testing on cases likely to be MSI-H and make testing more cost-effective.
Read the abstract in Laboratory Investigation
About Aigora
Aigora is a real-world data partner for life sciences and medtech companies. Through its network of more than 300 healthcare partner sites across Europe and beyond, Aigora discovers, sources, curates and delivers multimodal, regulatory-grade datasets tailored to specific research and development needs.